You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlprazolam
Accession NumberDB00404  (APRD00280)
TypeSmall Molecule
GroupsApproved, Illicit, Investigational
DescriptionA triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of panic disorders, with or without agoraphobia, and in generalized anxiety disorders. (From AMA Drug Evaluations Annual, 1994, p238)
Structure
Thumb
Synonyms
8-Chloro-1-methyl-6-phenyl-4H-S-triazolo(4,3-a)(1,4)benzodiazepine
Alprazolam
Xanax
External Identifiers
  • TUS-1
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlprazolamTablet1 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-30Not applicableUs
AlprazolamTablet0.25 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
AlprazolamTablet1 mg/1OralGreenstone LLC1981-10-16Not applicableUs
AlprazolamTablet.25 mg/1OralContract Pharmacy Services Pa1981-10-16Not applicableUs
AlprazolamTablet.5 mg/1OralContract Pharmacy Services Pa1981-10-16Not applicableUs
AlprazolamTablet0.25 mgOralSanis Health Inc2010-04-30Not applicableCanada
AlprazolamTablet0.5 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
AlprazolamTablet2 mg/1OralGreenstone LLC1981-10-16Not applicableUs
AlprazolamTablet1 mg/1OralContract Pharmacy Services Pa1981-10-16Not applicableUs
AlprazolamTablet0.50 mgOralSanis Health Inc2010-04-30Not applicableCanada
AlprazolamTablet1 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
AlprazolamTablet.25 mg/1Oralbryant ranch prepack1981-10-16Not applicableUs
AlprazolamTablet.25 mg/1OralGreenstone LLC1981-10-16Not applicableUs
AlprazolamTablet2 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
AlprazolamTablet2 mg/1Oralbryant ranch prepack1981-10-16Not applicableUs
AlprazolamTablet.5 mg/1OralGreenstone LLC1981-10-16Not applicableUs
Alprazolam Tablets 0.25Tablet0.25 mgOralPrempharm Inc1996-12-302005-08-05Canada
Alprazolam Tablets 0.5mgTablet0.5 mgOralPrempharm Inc1996-12-302005-08-05Canada
Alprazolam TsTablet2 mgOralPro Doc LimiteeNot applicableNot applicableCanada
Alprazolam XRTablet, extended release2 mg/1OralGreenstone LLC2003-01-17Not applicableUs
Alprazolam XRTablet, extended release3 mg/1OralLake Erie Medical DBA Quality Care Products LLC2003-01-17Not applicableUs
Alprazolam XRTablet, extended release.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2003-01-17Not applicableUs
Alprazolam XRTablet, extended release3 mg/1OralGreenstone LLC2003-01-17Not applicableUs
Alprazolam XRTablet, extended release1 mg/1OralLake Erie Medical DBA Quality Care Products LLC2003-01-17Not applicableUs
Alprazolam XRTablet, extended release.5 mg/1OralGreenstone LLC2003-01-17Not applicableUs
Alprazolam XRTablet, extended release2 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2003-01-17Not applicableUs
Alprazolam XRTablet, extended release1 mg/1OralGreenstone LLC2003-01-17Not applicableUs
Alprazolam-0.25 Tab 0.25mgTablet.25 mgOralPro Doc Limitee1991-12-31Not applicableCanada
Alprazolam-0.5 Tab 0.5mgTablet.5 mgOralPro Doc Limitee1991-12-31Not applicableCanada
Alprazolam-1Tablet1 mgOralPro Doc Limitee2004-04-01Not applicableCanada
Ipg-alprazolamTablet2 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-alprazolamTablet0.25 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-alprazolamTablet0.5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-alprazolamTablet1 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-alprazolamTablet0.25 mgOralJamp Pharma Corporation2014-05-15Not applicableCanada
Jamp-alprazolamTablet0.5 mgOralJamp Pharma Corporation2014-05-15Not applicableCanada
Jamp-alprazolamTablet2 mgOralJamp Pharma Corporation2015-10-25Not applicableCanada
Jamp-alprazolamTablet1 mgOralJamp Pharma Corporation2014-05-15Not applicableCanada
Mylan-alprazolamTablet0.25 mgOralMylan Pharmaceuticals Ulc1994-12-31Not applicableCanada
Mylan-alprazolamTablet1 mgOralMylan Pharmaceuticals Ulc1997-01-09Not applicableCanada
Mylan-alprazolamTablet0.5 mgOralMylan Pharmaceuticals Ulc1994-12-31Not applicableCanada
Mylan-alprazolamTablet2 mgOralMylan Pharmaceuticals Ulc1997-01-09Not applicableCanada
Nat-alprazolamTablet0.25 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-alprazolamTablet0.5 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-alprazolamTablet1 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-alprazolamTablet2 mgOralNatco Pharma (Canada) Inc2016-05-05Not applicableCanada
NiravamTablet, orally disintegrating.5 mg/1OralSTAT Rx USA LLC2005-01-20Not applicableUs
NiravamTablet, orally disintegrating2 mg/1OralJazz Pharmaceuticals, Inc.2005-04-012016-10-13Us
NiravamTablet, orally disintegrating.25 mg/1OralJazz Pharmaceuticals, Inc.2005-04-012016-10-13Us
NiravamTablet, orally disintegrating.5 mg/1OralJazz Pharmaceuticals, Inc.2005-04-012016-10-13Us
NiravamTablet, orally disintegrating1 mg/1OralJazz Pharmaceuticals, Inc.2005-04-012016-10-13Us
Ntp-alprazolamTablet0.25 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-alprazolamTablet0.5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-alpraz Tab 0.25mgTablet.25 mgOralNu Pharm Inc1991-12-312012-09-04Canada
Nu-alpraz Tab 0.5mgTablet.5 mgOralNu Pharm Inc1991-12-312012-09-04Canada
Ratio-alprazolamTablet0.5 mgOralRatiopharm Inc Division Of Teva Canada Limited1998-03-022006-08-04Canada
Ratio-alprazolamTablet0.25 mgOralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Riva-alprazolamTablet2 mgOralLaboratoire Riva Inc2015-06-05Not applicableCanada
Riva-alprazolamTablet1 mgOralLaboratoire Riva Inc2014-11-20Not applicableCanada
Riva-alprazolamTablet0.25 mgOralLaboratoire Riva Inc2014-11-20Not applicableCanada
Riva-alprazolamTablet0.5 mgOralLaboratoire Riva Inc2014-11-20Not applicableCanada
Riva-alprazolam 0.25 mgTablet0.25 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-alprazolam 0.5 mgTablet0.5 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Teva-alprazolamTablet0.25 mgOralTeva Canada Limited1991-12-31Not applicableCanada
Teva-alprazolamTablet0.5 mgOralTeva Canada Limited1993-09-23Not applicableCanada
XanaxTablet1 mg/1OralPharmacia And Upjohn Company Llc1981-10-16Not applicableUs
XanaxTablet2 mg/1OralPharmacia And Upjohn Company Llc1981-10-16Not applicableUs
XanaxTablet.25 mg/1OralPharmacia And Upjohn Company Llc1981-10-16Not applicableUs
XanaxTablet.5 mg/1OralPharmacia And Upjohn Company Llc1981-10-16Not applicableUs
Xanax Tab 0.25mgTablet0.25 mgOralPfizer Canada Inc1981-12-31Not applicableCanada
Xanax Tab 0.5mgTablet0.5 mgOralPfizer Canada Inc1981-12-31Not applicableCanada
Xanax Tab 1mgTablet1 mgOralPfizer Canada Inc1993-12-31Not applicableCanada
Xanax Ts Tab 2mgTablet2 mgOralPfizer Canada Inc1993-12-31Not applicableCanada
Xanax XRTablet, extended release.5 mg/1OralPharmacia And Upjohn Company Llc2003-01-17Not applicableUs
Xanax XRTablet, extended release1 mg/1OralPharmacia And Upjohn Company Llc2003-01-17Not applicableUs
Xanax XRTablet, extended release2 mg/1OralPharmacia And Upjohn Company Llc2003-01-17Not applicableUs
Xanax XRTablet, extended release3 mg/1OralPharmacia And Upjohn Company Llc2003-01-17Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlprazolamTablet.25 mg/1OralMylan Institutional Inc.1998-10-26Not applicableUs
AlprazolamTablet1 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-06-18Not applicableUs
AlprazolamTablet.5 mg/1OralAphena Pharma Solutions Tennessee, Llc1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralBionpharma Inc.2015-10-01Not applicableUs
AlprazolamTablet.25 mg/1OralPreferred Pharmaceuticals, Inc.2016-03-01Not applicableUs
AlprazolamTablet.5 mg/1OralMajor Pharmaceuticals2008-04-02Not applicableUs
AlprazolamTablet.5 mg/1OralKAISER FOUNDATION HOSPITALS2008-07-14Not applicableUs
AlprazolamTablet.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-03-28Not applicableUs
AlprazolamTablet.25 mg/1OralCardinal Health2007-03-282016-11-30Us
AlprazolamTablet.25 mg/1OralDIRECT RX2014-01-01Not applicableUs
AlprazolamTablet1 mg/1OralGolden State Medical Supply, Inc.1993-10-19Not applicableUs
AlprazolamTablet, extended release.5 mg/1OralProficient Rx LP2006-01-26Not applicableUs
AlprazolamTablet2 mg/1OralBoca Pharmacal, LLC2010-10-15Not applicableUs
AlprazolamTablet.5 mg/1OralAurobindo Pharma Limited2015-07-31Not applicableUs
AlprazolamTablet.5 mg/1OralSandoz Inc1995-12-29Not applicableUs
AlprazolamTablet1 mg/1OralSun Pharma Global FZE2010-06-18Not applicableUs
AlprazolamTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.1995-12-29Not applicableUs
AlprazolamTablet1 mg/1OralA S Medication Solutions Llc2010-06-18Not applicableUs
AlprazolamTablet, extended release2 mg/1OralRebel Distributors Corp.2009-12-03Not applicableUs
AlprazolamTablet.5 mg/1OralDAVA Pharmaceuticals, Inc.2007-03-28Not applicableUs
AlprazolamTablet.25 mg/1OralPreferred Pharmaceuticals, Inc.2010-06-18Not applicableUs
AlprazolamTablet.25 mg/1OralAmerican Health Packaging2013-05-282015-12-29Us
AlprazolamTablet, orally disintegrating1 mg/1OralActavis Pharma, Inc.2010-03-16Not applicableUs
AlprazolamTablet, extended release.5 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-05-242016-11-29Us
AlprazolamTablet2 mg/1OralREMEDYREPACK INC.2014-05-12Not applicableUs
AlprazolamTablet, extended release1 mg/1OralA S Medication Solutions Llc2011-05-04Not applicableUs
AlprazolamTablet1 mg/1OralREMEDYREPACK INC.2016-06-09Not applicableUs
AlprazolamTablet.5 mg/1OralCardinal Health1993-10-31Not applicableUs
AlprazolamTablet, extended release.5 mg/1OralMylan Pharmaceuticals Inc.2006-01-262017-04-30Us
AlprazolamTablet, extended release2 mg/1OralApotex Corp2008-11-12Not applicableUs
AlprazolamTablet, extended release2 mg/1OralAmneal Pharmaceuticals, LLC2009-12-03Not applicableUs
AlprazolamTablet.25 mg/1OralBlenheim Pharmacal, Inc.2013-05-22Not applicableUs
AlprazolamTablet.5 mg/1OralCardinal Health2009-12-31Not applicableUs
AlprazolamTablet.25 mg/1OralNu Care Pharmaceuticals, Inc.1995-12-29Not applicableUs
AlprazolamTablet1 mg/1OralApotex Corp.2007-01-19Not applicableUs
AlprazolamTablet, extended release.5 mg/1OralProficient Rx LP2011-06-07Not applicableUs
AlprazolamTablet.25 mg/1OralContract Pharmacy Services Pa2011-03-25Not applicableUs
AlprazolamTablet.25 mg/1OralBlenheim Pharmacal, Inc.2011-09-14Not applicableUs
AlprazolamTablet2 mg/1OralRebel Distributors Corp.1998-03-25Not applicableUs
AlprazolamTablet.25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-01Not applicableUs
AlprazolamTablet.25 mg/1OralA S Medication Solutions Llc2008-09-25Not applicableUs
AlprazolamTablet.5 mg/1OralPd Rx Pharmaceuticals, Inc.2009-12-31Not applicableUs
AlprazolamTablet.25 mg/1OralPreferred Pharmaceuticals, Inc.1999-12-29Not applicableUs
AlprazolamTablet.5 mg/1OralLife Line Home Care Services, Inc.2012-01-26Not applicableUs
AlprazolamTablet.5 mg/1OralCardinal Health2008-04-02Not applicableUs
AlprazolamTablet, orally disintegrating.25 mg/1OralPar Pharmaceutical, Inc.2009-01-09Not applicableUs
AlprazolamTablet2 mg/1OralActavis Pharma, Inc.1995-01-03Not applicableUs
AlprazolamTablet.25 mg/1OralKAISER FOUNDATION HOSPITALS2011-06-08Not applicableUs
AlprazolamTablet, extended release1 mg/1OralPreferred Pharmaceuticals, Inc.2012-11-15Not applicableUs
AlprazolamTablet2 mg/1OralPhysicians Total Care, Inc.2009-09-16Not applicableUs
AlprazolamTablet2 mg/1OralA S Medication Solutions2010-06-18Not applicableUs
AlprazolamTablet.25 mg/1OralPd Rx Pharmaceuticals, Inc.2008-09-25Not applicableUs
AlprazolamTablet.5 mg/1OralQualitest Pharmaceuticals2008-09-252016-12-31Us
AlprazolamTablet1 mg/1OralDIRECT RX2015-01-01Not applicableUs
AlprazolamTablet.25 mg/1OralBoca Pharmacal, LLC2010-10-15Not applicableUs
AlprazolamTablet, extended release2 mg/1OralAurobindo Pharma Limited2011-06-07Not applicableUs
AlprazolamTablet.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1995-01-03Not applicableUs
AlprazolamTablet.5 mg/1OralSTAT Rx USA LLC2011-03-25Not applicableUs
AlprazolamTablet2 mg/1OralMedsource Pharmaceuticals1995-01-03Not applicableUs
AlprazolamTablet.25 mg/1OralUnit Dose Services1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralAidarex Pharmaceuticals LLC2007-03-28Not applicableUs
AlprazolamTablet.5 mg/1OralRed Pharm2008-06-01Not applicableUs
AlprazolamTablet.5 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-12Not applicableUs
AlprazolamTablet1 mg/1OralMylan Pharmaceuticals Inc.1994-01-28Not applicableUs
AlprazolamTablet.25 mg/1OralRebel Distributors Corp.1999-12-29Not applicableUs
AlprazolamTablet2 mg/1OralSun Pharma Global FZE2010-06-18Not applicableUs
AlprazolamTablet.5 mg/1OralMylan Institutional Inc.1998-10-23Not applicableUs
AlprazolamTablet.25 mg/1OralRebel Distributors Corp2010-06-18Not applicableUs
AlprazolamTablet.25 mg/1OralAmerican Health Packaging2013-09-04Not applicableUs
AlprazolamTablet.5 mg/1OralBionpharma Inc.2015-10-01Not applicableUs
AlprazolamTablet2 mg/1OralPd Rx Pharmaceuticals, Inc.1998-03-25Not applicableUs
AlprazolamTablet1 mg/1OralMajor Pharmaceuticals2008-04-02Not applicableUs
AlprazolamTablet.25 mg/1OralActavis Pharma, Inc.1995-01-03Not applicableUs
AlprazolamTablet2 mg/1OralAmerican Health Packaging2016-05-02Not applicableUs
AlprazolamTablet.5 mg/1OralCardinal Health2007-03-282016-11-30Us
AlprazolamTablet.25 mg/1OralA S Medication Solutions2007-03-28Not applicableUs
AlprazolamTablet2 mg/1OralGolden State Medical Supply, Inc.1993-10-19Not applicableUs
AlprazolamTablet1 mg/1OralProficient Rx LP1995-12-29Not applicableUs
AlprazolamTablet1 mg/1OralAurobindo Pharma Limited2015-07-31Not applicableUs
AlprazolamTablet1 mg/1OralSandoz Inc1995-12-29Not applicableUs
AlprazolamTablet1 mg/1OralQualitest Pharmaceuticals2008-09-252016-10-26Us
AlprazolamTablet.25 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
AlprazolamTablet.5 mg/1OralMedsource Pharmaceuticals2008-09-25Not applicableUs
AlprazolamTablet2 mg/1OralA S Medication Solutions Llc2010-10-15Not applicableUs
AlprazolamTablet.5 mg/1OralAidarex Pharmaceuticals LLC2007-03-28Not applicableUs
AlprazolamTablet1 mg/1OralDAVA Pharmaceuticals, Inc.2007-03-28Not applicableUs
AlprazolamTablet2 mg/1OralPreferred Pharmaceuticals Inc.2015-10-19Not applicableUs
AlprazolamTablet.5 mg/1OralAmerican Health Packaging2013-05-282015-12-29Us
AlprazolamTablet, orally disintegrating2 mg/1OralActavis Pharma, Inc.2010-03-16Not applicableUs
AlprazolamTablet, extended release1 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-05-242016-11-29Us
AlprazolamTablet.25 mg/1OralPreferred Pharmaceuticals, Inc.2010-03-16Not applicableUs
AlprazolamTablet.25 mg/1OralPhysicians Total Care, Inc.2005-03-17Not applicableUs
AlprazolamTablet1 mg/1OralA S Medication Solutions2010-10-15Not applicableUs
AlprazolamTablet1 mg/1OralCardinal Health1993-10-31Not applicableUs
AlprazolamTablet, extended release1 mg/1OralMylan Pharmaceuticals Inc.2006-01-262017-09-30Us
AlprazolamTablet, extended release3 mg/1OralApotex Corp2008-11-12Not applicableUs
AlprazolamTablet.25 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2014-04-29Not applicableUs
AlprazolamTablet, extended release3 mg/1OralAmneal Pharmaceuticals, LLC2009-12-03Not applicableUs
AlprazolamTablet, orally disintegrating.5 mg/1OralPar Pharmaceutical, Inc.2009-01-09Not applicableUs
AlprazolamTablet.5 mg/1OralNu Care Pharmaceuticals, Inc.2016-09-21Not applicableUs
AlprazolamTablet1 mg/1OralCardinal Health2009-12-31Not applicableUs
AlprazolamTablet.25 mg/1OralPd Rx Pharmaceuticals, Inc.2007-03-28Not applicableUs
AlprazolamTablet2 mg/1OralApotex Corp.2007-01-19Not applicableUs
AlprazolamTablet.5 mg/1OralTYA Pharmaceuticals2010-06-18Not applicableUs
AlprazolamTablet.5 mg/1OralContract Pharmacy Services Pa2011-03-25Not applicableUs
AlprazolamTablet.25 mg/1OralBlenheim Pharmacal, Inc.2009-12-16Not applicableUs
AlprazolamTablet, extended release.5 mg/1OralRebel Distributors Corp.2009-12-03Not applicableUs
AlprazolamTablet2 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-01Not applicableUs
AlprazolamTablet.5 mg/1OralA S Medication Solutions Llc2008-09-25Not applicableUs
AlprazolamTablet.25 mg/1OralPd Rx Pharmaceuticals, Inc.2011-09-07Not applicableUs
AlprazolamTablet.5 mg/1OralPreferred Pharmaceuticals, Inc.1999-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralMc Kesson Contract Packaging2011-10-24Not applicableUs
AlprazolamSolution, concentrate1 mg/mLOralWest Ward Pharmaceuticals Corp.1993-10-31Not applicableUs
AlprazolamTablet2 mg/1OralMylan Pharmaceuticals Inc.1994-01-28Not applicableUs
AlprazolamTablet.5 mg/1OralKAISER FOUNDATION HOSPITALS2011-06-08Not applicableUs
AlprazolamTablet.25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralCardinal Health2007-12-03Not applicableUs
AlprazolamTablet.25 mg/1OralA S Medication Solutions1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralGolden State Medical Supply, Inc.1993-10-19Not applicableUs
AlprazolamTablet.5 mg/1OralProficient Rx LP1995-12-29Not applicableUs
AlprazolamTablet.5 mg/1OralBoca Pharmacal, LLC2010-10-15Not applicableUs
AlprazolamTablet, extended release3 mg/1OralAurobindo Pharma Limited2011-06-07Not applicableUs
AlprazolamTablet1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1995-01-03Not applicableUs
AlprazolamTablet1 mg/1OralSTAT Rx USA LLC2011-03-25Not applicableUs
AlprazolamTablet.25 mg/1OralSun Pharma Global FZE2010-06-18Not applicableUs
AlprazolamTablet.5 mg/1OralUnit Dose Services1995-12-29Not applicableUs
AlprazolamTablet, extended release1 mg/1OralAidarex Pharmaceuticals LLC2009-12-03Not applicableUs
AlprazolamTablet.25 mg/1OralAphena Pharma Solutions Tennessee, Llc1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-12Not applicableUs
AlprazolamTablet2 mg/1OralAurobindo Pharma Limited2015-07-31Not applicableUs
AlprazolamTablet2 mg/1OralSandoz Inc1998-03-25Not applicableUs
AlprazolamTablet.5 mg/1OralRebel Distributors Corp.1999-12-29Not applicableUs
AlprazolamTablet.5 mg/1OralREMEDYREPACK INC.2011-04-21Not applicableUs
AlprazolamTablet1 mg/1OralMylan Institutional Inc.1998-10-23Not applicableUs
AlprazolamTablet.25 mg/1OralRebel Distributors Corp2010-06-18Not applicableUs
AlprazolamTablet.5 mg/1OralAmerican Health Packaging2013-09-04Not applicableUs
AlprazolamTablet1 mg/1OralBionpharma Inc.2015-10-01Not applicableUs
AlprazolamTablet.25 mg/1OralCardinal Health2008-04-02Not applicableUs
AlprazolamTablet2 mg/1OralMajor Pharmaceuticals2008-04-02Not applicableUs
AlprazolamTablet.5 mg/1OralActavis Pharma, Inc.1995-01-03Not applicableUs
AlprazolamTablet1 mg/1OralSt. Marys Medical Park Pharmacy2016-04-01Not applicableUs
AlprazolamTablet1 mg/1OralCardinal Health2007-03-282016-11-30Us
AlprazolamTablet2 mg/1OralA S Medication Solutions2007-03-28Not applicableUs
AlprazolamTablet.25 mg/1OralApotex Corp.2007-01-19Not applicableUs
AlprazolamTablet2 mg/1OralProficient Rx LP1998-03-25Not applicableUs
AlprazolamTablet.5 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2014-04-29Not applicableUs
AlprazolamTablet, extended release.5 mg/1OralAurobindo Pharma Limited2011-06-07Not applicableUs
AlprazolamTablet2 mg/1OralQualitest Pharmaceuticals2008-09-252016-10-26Us
AlprazolamTablet.5 mg/1OralApotheca, Inc2000-01-18Not applicableUs
AlprazolamTablet1 mg/1OralMedsource Pharmaceuticals1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralA S Medication Solutions Llc2010-10-15Not applicableUs
AlprazolamTablet1 mg/1OralAidarex Pharmaceuticals LLC2007-03-28Not applicableUs
AlprazolamTablet2 mg/1OralDAVA Pharmaceuticals, Inc.2007-03-28Not applicableUs
AlprazolamTablet, extended release1 mg/1OralPreferred Pharmaceuticals, Inc.2013-04-22Not applicableUs
AlprazolamTablet1 mg/1OralAmerican Health Packaging2013-05-282015-12-29Us
AlprazolamTablet.25 mg/1OralMylan Pharmaceuticals Inc.2012-07-23Not applicableUs
AlprazolamTablet, extended release2 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-05-242016-11-29Us
AlprazolamTablet.5 mg/1OralPreferred Pharmaceuticals, Inc.2010-03-16Not applicableUs
AlprazolamTablet.5 mg/1OralPhysicians Total Care, Inc.2007-10-26Not applicableUs
AlprazolamTablet.5 mg/1OralA S Medication Solutions2010-10-15Not applicableUs
AlprazolamTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.2009-12-31Not applicableUs
AlprazolamTablet.5 mg/1OralRed Pharm Drug, Inc.2007-03-28Not applicableUs
AlprazolamTablet.25 mg/1OralREMEDYREPACK INC.2015-03-172016-10-13Us
AlprazolamTablet.5 mg/1OralMc Kesson Contract Packaging2011-10-17Not applicableUs
AlprazolamTablet, orally disintegrating.25 mg/1OralActavis Pharma, Inc.2010-03-16Not applicableUs
AlprazolamTablet, orally disintegrating1 mg/1OralPar Pharmaceutical, Inc.2009-01-09Not applicableUs
AlprazolamTablet1 mg/1OralNu Care Pharmaceuticals, Inc.1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralCardinal Health2009-12-31Not applicableUs
AlprazolamTablet.5 mg/1OralDIRECT RX2014-01-01Not applicableUs
AlprazolamTablet, extended release.5 mg/1OralApotex Corp2008-11-12Not applicableUs
AlprazolamTablet1 mg/1Oralbryant ranch prepack2008-04-02Not applicableUs
AlprazolamTablet, extended release.5 mg/1OralAmneal Pharmaceuticals, LLC2009-12-03Not applicableUs
AlprazolamTablet1 mg/1OralContract Pharmacy Services Pa2011-03-25Not applicableUs
AlprazolamTablet1 mg/1OralBlenheim Pharmacal, Inc.2010-04-13Not applicableUs
AlprazolamTablet, extended release1 mg/1OralRebel Distributors Corp.2009-12-03Not applicableUs
AlprazolamTablet.25 mg/1OralA S Medication Solutions Llc2010-06-18Not applicableUs
AlprazolamTablet1 mg/1OralA S Medication Solutions Llc2008-09-25Not applicableUs
AlprazolamTablet.5 mg/1OralPd Rx Pharmaceuticals, Inc.2007-03-28Not applicableUs
AlprazolamTablet1 mg/1OralPreferred Pharmaceuticals, Inc.2014-10-20Not applicableUs
AlprazolamTablet1 mg/1OralAphena Pharma Solutions Tennessee, Llc1995-12-29Not applicableUs
AlprazolamTablet1 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-16Not applicableUs
AlprazolamTablet.25 mg/1OralMajor Pharmaceuticals2008-04-02Not applicableUs
AlprazolamTablet.25 mg/1OralKAISER FOUNDATION HOSPITALS2008-07-14Not applicableUs
AlprazolamTablet.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1995-12-29Not applicableUs
AlprazolamTablet.5 mg/1OralCardinal Health2007-12-03Not applicableUs
AlprazolamTablet.25 mg/1OralDIRECT RX2014-01-01Not applicableUs
AlprazolamTablet.5 mg/1OralGolden State Medical Supply, Inc.1993-10-19Not applicableUs
AlprazolamTablet1 mg/1OralProficient Rx LP1994-01-28Not applicableUs
AlprazolamTablet1 mg/1OralBoca Pharmacal, LLC2010-10-15Not applicableUs
AlprazolamTablet.25 mg/1OralAurobindo Pharma Limited2015-07-31Not applicableUs
AlprazolamTablet.25 mg/1OralSandoz Inc1995-12-29Not applicableUs
AlprazolamTablet.25 mg/1OralSTAT Rx USA LLC1993-10-31Not applicableUs
AlprazolamTablet.5 mg/1OralSun Pharma Global FZE2010-06-18Not applicableUs
AlprazolamTablet1 mg/1OralUnit Dose Services1995-12-29Not applicableUs
AlprazolamTablet1 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1995-12-29Not applicableUs
AlprazolamTablet, extended release1 mg/1OralProficient Rx LP2011-06-07Not applicableUs
AlprazolamTablet1 mg/1OralDispensing Solutions, Inc.2008-09-25Not applicableUs
AlprazolamTablet.25 mg/1OralBlenheim Pharmacal, Inc.2010-12-10Not applicableUs
AlprazolamTablet1 mg/1OralRebel Distributors Corp.1999-12-29Not applicableUs
AlprazolamTablet.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-04-01Not applicableUs
AlprazolamTablet1 mg/1OralRebel Distributors Corp2010-06-18Not applicableUs
AlprazolamTablet1 mg/1OralPreferred Pharmaceuticals, Inc.1999-12-29Not applicableUs
AlprazolamTablet2 mg/1OralBionpharma Inc.2015-10-01Not applicableUs
AlprazolamTablet1 mg/1OralCardinal Health2008-04-02Not applicableUs
AlprazolamTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.2007-03-28Not applicableUs
AlprazolamTablet1 mg/1OralActavis Pharma, Inc.1995-01-03Not applicableUs
AlprazolamTablet.25 mg/1OralREMEDYREPACK INC.2016-06-27Not applicableUs
AlprazolamTablet.25 mg/1OralCardinal Health2013-09-04Not applicableUs
AlprazolamTablet2 mg/1OralUnit Dose Services2007-03-28Not applicableUs
AlprazolamTablet.5 mg/1OralApotex Corp.2007-01-19Not applicableUs
AlprazolamTablet.5 mg/1OralPd Rx Pharmaceuticals, Inc.2008-09-25Not applicableUs
AlprazolamTablet.25 mg/1OralQualitest Pharmaceuticals2008-09-252016-12-31Us
AlprazolamTablet1 mg/1OralDIRECT RX2014-01-01Not applicableUs
AlprazolamTablet1 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2014-04-29Not applicableUs
AlprazolamTablet, extended release1 mg/1OralAurobindo Pharma Limited2011-06-07Not applicableUs
AlprazolamTablet.25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1995-01-03Not applicableUs
AlprazolamTablet1 mg/1OralApotheca, Inc2012-06-30Not applicableUs
AlprazolamTablet, extended release1 mg/1OralMedsource Pharmaceuticals2011-06-07Not applicableUs
AlprazolamTablet2 mg/1OralUnit Dose Services1995-01-03Not applicableUs
AlprazolamTablet2 mg/1OralAidarex Pharmaceuticals LLC2007-03-28Not applicableUs
AlprazolamTablet.25 mg/1OralRed Pharm Drug Inc.2008-02-01Not applicableUs
AlprazolamTablet1 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-12Not applicableUs
AlprazolamTablet.5 mg/1OralMylan Pharmaceuticals Inc.2010-02-25Not applicableUs
AlprazolamTablet, extended release3 mg/1OralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-05-242016-11-29Us
AlprazolamTablet1 mg/1OralPreferred Pharmaceuticals, Inc.2010-03-16Not applicableUs
AlprazolamTablet1 mg/1OralPhysicians Total Care, Inc.2006-09-13Not applicableUs
AlprazolamTablet.5 mg/1OralA S Medication Solutions2007-03-28Not applicableUs
AlprazolamTablet.5 mg/1OralPreferred Pharmaceuticals, Inc.2010-06-18Not applicableUs
AlprazolamTablet1 mg/1OralMc Kesson Contract Packaging2011-10-17Not applicableUs
AlprazolamTablet, orally disintegrating.5 mg/1OralActavis Pharma, Inc.2010-03-16Not applicableUs
AlprazolamTablet, orally disintegrating2 mg/1OralPar Pharmaceutical, Inc.2009-01-09Not applicableUs
AlprazolamTablet1 mg/1OralPreferred Pharmaceuticals Inc.2016-04-28Not applicableUs
AlprazolamTablet.25 mg/1OralCardinal Health1993-10-31Not applicableUs
AlprazolamTablet1 mg/1OralA S Medication Solutions2007-03-28Not applicableUs
AlprazolamTablet, extended release1 mg/1OralApotex Corp2008-11-12Not applicableUs
AlprazolamTablet, extended release1 mg/1OralAmneal Pharmaceuticals, LLC2009-12-03Not applicableUs
AlprazolamTablet.25 mg/1OralDAVA Pharmaceuticals, Inc.2007-03-28Not applicableUs
AlprazolamTablet2 mg/1OralBlenheim Pharmacal, Inc.2010-04-23Not applicableUs
AlprazolamTablet, extended release2 mg/1OralRebel Distributors Corp.2009-12-03Not applicableUs
AlprazolamTablet.5 mg/1OralA S Medication Solutions Llc2010-06-18Not applicableUs
AlprazolamTablet2 mg/1OralA S Medication Solutions Llc2010-10-15Not applicableUs
AlprazolamTablet1 mg/1OralPd Rx Pharmaceuticals, Inc.2008-09-25Not applicableUs
Alprazolam ERTablet, extended release2 mg/1OralSTAT Rx USA LLC2007-03-28Not applicableUs
Alprazolam Extended ReleaseTablet, extended release.5 mg/1Oralbryant ranch prepack2007-02-13Not applicableUs
Alprazolam Extended ReleaseTablet, extended release2 mg/1OralActavis Elizabeth LLC2007-02-13Not applicableUs
Alprazolam Extended ReleaseTablet, extended release3 mg/1OralCore Pharma, Llc2007-03-282016-03-16Us
Alprazolam Extended ReleaseTablet, extended release.5 mg/1OralCore Pharma, Llc2007-03-282016-03-16Us
Alprazolam Extended ReleaseTablet, extended release.5 mg/1OralActavis Elizabeth LLC2007-02-13Not applicableUs
Alprazolam Extended ReleaseTablet, extended release1 mg/1OralCore Pharma, Llc2007-03-282016-03-16Us
Alprazolam Extended ReleaseTablet, extended release1 mg/1OralActavis Elizabeth LLC2007-02-13Not applicableUs
Alprazolam Extended ReleaseTablet, extended release2 mg/1OralCore Pharma, Llc2007-03-282016-03-16Us
Alprazolam Extended ReleaseTablet, extended release3 mg/1OralActavis Elizabeth LLC2007-02-13Not applicableUs
Alprazolam Extended-releaseTablet, extended release.5 mg/1Oralbryant ranch prepack2007-03-28Not applicableUs
Alprazolam Extended-releaseTablet, extended release1 mg/1OralH.J. Harkins Company, Inc.2007-03-28Not applicableUs
Alprazolam Extended-releaseTablet, extended release.5 mg/1Oralbryant ranch prepack2007-03-28Not applicableUs
Apo-alprazTablet1 mgOralApotex Inc2001-04-16Not applicableCanada
Apo-alpraz Tab 0.25mgTablet0.25 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-alpraz Tab 0.5mgTablet.5 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-alpraz TsTablet2 mgOralApotex Inc2001-04-16Not applicableCanada
XanaxTablet1 mg/1OralDIRECT RX2016-06-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlplaxNot Available
AlprazolanNot Available
AlpronaxNot Available
AlproxNot Available
AlvizNot Available
CassadanNot Available
EsparonNot Available
RalozamNot Available
RestylNot Available
SolanaxNot Available
TafilNot Available
TrankimazinNot Available
TranquinalNot Available
XanorNot Available
Brand mixtures
NameLabellerIngredients
GabazolaminePhysician Therapeutics Llc
Gabazolamine-0.5Physician Therapeutics Llc
Sentrazolam AmPhysician Therapeutics Llc
SaltsNot Available
Categories
UNIIYU55MQ3IZY
CAS number28981-97-7
WeightAverage: 308.765
Monoisotopic: 308.082874143
Chemical FormulaC17H13ClN4
InChI KeyVREFGVBLTWBCJP-UHFFFAOYSA-N
InChI
InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3
IUPAC Name
12-chloro-3-methyl-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene
SMILES
CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
Pharmacology
IndicationFor the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia.
Structured Indications
PharmacodynamicsAlprazolam, a benzodiazepine, is used to treat panic disorder and anxiety disorder. Unlike chlordiazepoxide, clorazepate, and prazepam, alprazolam has a shorter half-life and metabolites with minimal activity. Like other triazolo benzodiazepines such as triazolam, alprazolam may have significant drug interactions involving the hepatic cytochrome P-450 3A4 isoenzyme. Clinically, all benzodiazepines cause a dose-related central nervous system depressant activity varying from mild impairment of task performance to hypnosis. Unlike other benzodiazepines, alprazolam may also have some antidepressant activity, although clinical evidence of this is lacking.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
TargetKindPharmacological actionActionsOrganismUniProt ID
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionReadily absorbed from the gastrointestinal tract. Bioavailability is 80-90%.
Volume of distributionNot Available
Protein binding80% (mainly to albumin)
Metabolism

Hepatic. Hydroxylated in the liver to α-hydroxyalprazolam, which is also active. This and other metabolites are later excreted in urine as glucuronides.

SubstrateEnzymesProduct
Alprazolam
alpha-HydroxyalprazolamDetails
Alprazolam
4-hydroxyalprazolamDetails
Route of eliminationAlprazolam and its metabolites are excreted primarily in the urine.
Half life6.3-26.9 hours
Clearance
  • 2.13 +/- 0.54 mL/min/kg [CYP3A inducers]
  • 0.90 +/- 0.21 mL/min/kg [without CYP3A inducers]
ToxicityOral, mouse: LD50=1020 mg/kg. Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Alprazolam is combined with 1,1,1,2 Tetrafluoroethane.Investigational
1,10-PhenanthrolineThe serum concentration of Alprazolam can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Alprazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Alprazolam can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Alprazolam can be decreased when combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Alprazolam is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alfentanil.Approved, Illicit
AlogliptinThe serum concentration of Alprazolam can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Alprazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alphacetylmethadol.Experimental, Illicit
Ambroxol acefyllinateThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Ambroxol acefyllinate.Experimental
AminophyllineThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Alprazolam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Alprazolam can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Alprazolam can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Alprazolam can be increased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Alprazolam can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Alprazolam can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Alprazolam can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Alprazolam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Alprazolam can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Alprazolam can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Alprazolam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Azaperone.Vet Approved
AzelastineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Alprazolam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Barbital.Illicit
BatimastatThe serum concentration of Alprazolam can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Alprazolam can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Alprazolam can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Alprazolam is combined with Benzyl alcohol.Approved
BexaroteneThe serum concentration of Alprazolam can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Alprazolam can be increased when it is combined with Bi201335.Investigational
BivalirudinThe serum concentration of Alprazolam can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Alprazolam can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Alprazolam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Alprazolam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alprazolam.Approved, Investigational
BuprenorphineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alprazolam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butorphanol.Approved, Illicit, Vet Approved
CandoxatrilThe serum concentration of Alprazolam can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Alprazolam can be increased when it is combined with Candoxatrilat.Experimental
CapecitabineThe metabolism of Alprazolam can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Alprazolam can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Alprazolam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carbinoxamine.Approved
CarbomycinThe serum concentration of Alprazolam can be increased when it is combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Alprazolam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Alprazolam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Alprazolam can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Alprazolam can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Alprazolam can be increased when it is combined with Cilazapril.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Alprazolam is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Alprazolam can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Alprazolam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Alprazolam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Clozapine.Approved
CobicistatThe metabolism of Alprazolam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Alprazolam.Approved, Illicit
ConivaptanThe serum concentration of Alprazolam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Alprazolam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Alprazolam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of Alprazolam can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Alprazolam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alprazolam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Alprazolam can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Alprazolam can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Alprazolam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Alprazolam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Alprazolam can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Alprazolam is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Alprazolam can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Alprazolam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Alprazolam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Diphenoxylate.Approved, Illicit
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Alprazolam.Approved
DoramectinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Doxepin.Approved
DoxycyclineThe metabolism of Alprazolam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Alprazolam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit
DronedaroneThe metabolism of Alprazolam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Dyphylline.Approved
EcabetThe serum concentration of Alprazolam can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Alprazolam is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Alprazolam can be increased when it is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Alprazolam can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Alprazolam can be increased when it is combined with Elafin.Investigational
EnalaprilThe serum concentration of Alprazolam can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Alprazolam can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Alprazolam can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Alprazolam.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Alprazolam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe serum concentration of Alprazolam can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Alprazolam is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Alprazolam can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alprazolam.Approved
EthanolAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alprazolam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Alprazolam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Alprazolam can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fexofenadine.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Alprazolam.Approved
FloxuridineThe metabolism of Alprazolam can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Alprazolam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Alprazolam can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Alprazolam can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Alprazolam can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Alprazolam can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Alprazolam can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Alprazolam can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Alprazolam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Alprazolam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Alprazolam is combined with gabapentin enacarbil.Approved
GabexateThe serum concentration of Alprazolam can be increased when it is combined with Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GeldanamycinThe serum concentration of Alprazolam can be increased when it is combined with Geldanamycin.Experimental
GemfibrozilThe metabolism of Alprazolam can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Glutethimide.Approved, Illicit
GM6001The serum concentration of Alprazolam can be increased when it is combined with GM6001.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Hexobarbital.Approved
HirulogThe serum concentration of Alprazolam can be increased when it is combined with Hirulog.Experimental
HyaluronidaseThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alprazolam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved
IdelalisibThe serum concentration of Alprazolam can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of Alprazolam can be increased when it is combined with idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Iloperidone.Approved
ImatinibThe metabolism of Alprazolam can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Alprazolam can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Alprazolam can be increased when it is combined with Indinavir.Approved
IrbesartanThe metabolism of Alprazolam can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Alprazolam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe serum concentration of Alprazolam can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsradipineThe metabolism of Alprazolam can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Alprazolam can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Alprazolam can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Alprazolam can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Alprazolam can be increased when it is combined with Josamycin.Approved
KetamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Alprazolam can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Alprazolam can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Alprazolam can be increased when it is combined with Kitasamycin.Experimental
LamotrigineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lamotrigine.Approved, Investigational
LeflunomideThe metabolism of Alprazolam can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinThe serum concentration of Alprazolam can be increased when it is combined with Lepirudin.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Alprazolam.Approved, Vet Approved
LinagliptinThe serum concentration of Alprazolam can be increased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Alprazolam can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lofentanil.Illicit
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Alprazolam.Approved
LopinavirThe serum concentration of Alprazolam can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alprazolam.Approved
LosartanThe metabolism of Alprazolam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Alprazolam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Alprazolam is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Alprazolam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Alprazolam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Alprazolam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alprazolam.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Metaxalone.Approved
MethadoneAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methohexital.Approved
MethotrimeprazineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methylphenobarbital.Approved
MetyrosineAlprazolam may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Alprazolam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Alprazolam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Investigational
MirtazapineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Alprazolam can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Alprazolam can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Alprazolam can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Alprazolam.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Alprazolam can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Investigational
NafamostatThe serum concentration of Alprazolam can be increased when it is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Alprazolam can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nalbuphine.Approved
NCX 4016The serum concentration of Alprazolam can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe metabolism of Alprazolam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Alprazolam can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Alprazolam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Alprazolam can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Alprazolam can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Alprazolam can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Alprazolam.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nitrazepam.Approved
NitroaspirinThe serum concentration of Alprazolam can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alprazolam.Approved, Investigational
OlaparibThe metabolism of Alprazolam can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Alprazolam can be increased when it is combined with Oleandomycin.Vet Approved
OlopatadineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Alprazolam can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Alprazolam can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe metabolism of Alprazolam can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Alprazolam is combined with Opium.Approved, Illicit
OrphenadrineAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Alprazolam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Alprazolam can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Alprazolam can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Alprazolam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paliperidone.Approved
ParaldehydeAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParitaprevirThe serum concentration of Alprazolam can be increased when it is combined with Paritaprevir.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Alprazolam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved
PerazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perazine.Investigational
PerindoprilThe serum concentration of Alprazolam can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pethidine.Approved
PhenobarbitalThe metabolism of Alprazolam can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Alprazolam.Approved, Vet Approved
PhosphoramidonThe serum concentration of Alprazolam can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe serum concentration of Pimozide can be increased when it is combined with Alprazolam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Alprazolam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleAlprazolam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alprazolam.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prilocaine.Approved
PrimidoneThe metabolism of Alprazolam can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Alprazolam can be increased when it is combined with Prinomastat.Investigational
ProcaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Alprazolam is combined with PSD502.Investigational
PyrimethamineThe metabolism of Alprazolam can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Alprazolam can be increased when it is combined with Quinapril.Approved, Investigational
QuinineThe metabolism of Alprazolam can be decreased when combined with Quinine.Approved
RacecadotrilThe serum concentration of Alprazolam can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Alprazolam can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Alprazolam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remifentanil.Approved
RemikirenThe serum concentration of Alprazolam can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Alprazolam.Approved
RifabutinThe metabolism of Alprazolam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Alprazolam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Alprazolam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Alprazolam can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Alprazolam can be increased when it is combined with Rivaroxaban.Approved
RomifidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Romifidine.Vet Approved
RopiniroleAlprazolam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alprazolam.Approved
RotigotineAlprazolam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Alprazolam.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Alprazolam is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Alprazolam is combined with Sage 547.Investigational
SaquinavirThe serum concentration of Alprazolam can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Alprazolam can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Alprazolam can be increased when combined with Secobarbital.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Alprazolam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Alprazolam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Alprazolam can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Alprazolam can be increased when it is combined with Sitagliptin.Approved, Investigational
Sodium oxybateAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SolithromycinThe serum concentration of Alprazolam can be increased when it is combined with Solithromycin.Investigational
SorafenibThe metabolism of Alprazolam can be decreased when combined with Sorafenib.Approved, Investigational
SpiraprilThe serum concentration of Alprazolam can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Alprazolam can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Alprazolam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Alprazolam can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Alprazolam can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Alprazolam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alprazolam.Approved
SuvorexantAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Alprazolam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe serum concentration of Alprazolam can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Alprazolam can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Alprazolam.Approved
TemocaprilThe serum concentration of Alprazolam can be increased when it is combined with Temocapril.Experimental, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrodotoxin.Investigational
ThalidomideAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thioridazine.Approved
ThiorphanThe serum concentration of Alprazolam can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tiapride.Investigational
TicagrelorThe metabolism of Alprazolam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Alprazolam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tiletamine.Vet Approved
TipranavirThe serum concentration of Alprazolam can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Alprazolam can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Alprazolam can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Alprazolam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Alprazolam.Approved, Investigational
TrandolaprilThe serum concentration of Alprazolam can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe metabolism of Alprazolam can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Triprolidine.Approved
TroleandomycinThe serum concentration of Alprazolam can be increased when it is combined with Troleandomycin.Approved
TylosinThe serum concentration of Alprazolam can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Alprazolam can be increased when it is combined with Ubenimex.Experimental
Uc1010The risk or severity of adverse effects can be increased when Alprazolam is combined with Uc1010.Investigational
UlinastatinThe serum concentration of Alprazolam can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Alprazolam.Approved, Investigational
ValsartanThe metabolism of Alprazolam can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Alprazolam can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Alprazolam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Alprazolam is combined with Vigabatrin.Approved
VildagliptinThe serum concentration of Alprazolam can be increased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe metabolism of Alprazolam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Vortioxetine.Approved
XimelagatranThe serum concentration of Alprazolam can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Xylazine.Vet Approved
Ym150The serum concentration of Alprazolam can be increased when it is combined with Ym150.Investigational
YohimbineThe therapeutic efficacy of Alprazolam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZafirlukastThe metabolism of Alprazolam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Alprazolam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zolazepam.Vet Approved
ZolpidemAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid taking with grapefruit juice.
  • Take with food.
References
Synthesis Reference

Hester, J.B., Jr.; US. Patent 3,681,343; August 1,1972; assigned to The Upjohn Company. Hester, J.B., Jr.; US.Patent 3,781,289; December 25,1973;assigned to The Upjohn Company. Hester, J.B., Jr.; U S . Patent 3,709898; January 9,1973; assigned to The Upjohn Company.

General References
  1. Risse SC, Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA: Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry. 1990 May;51(5):206-9. [PubMed:2335496 ]
  2. Wolf B, Griffiths RR: Physical dependence on benzodiazepines: differences within the class. Drug Alcohol Depend. 1991 Dec 31;29(2):153-6. [PubMed:1686752 ]
  3. Haque W, Watson DJ, Bryant SG: Death following suspected alprazolam withdrawal seizures: a case report. Tex Med. 1990 Jan;86(1):44-7. [PubMed:2300914 ]
  4. Hori A: Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci. 1998 Feb;52(1):13-9. [PubMed:9682928 ]
  5. Garcia-Algar O, Lopez-Vilchez MA, Martin I, Mur A, Pellegrini M, Pacifici R, Rossi S, Pichini S: Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin Toxicol (Phila). 2007;45(3):295-8. [PubMed:17453885 ]
External Links
ATC CodesN05BA12
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelDownload (63.6 KB)
MSDSDownload (47.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9794
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5099
P-glycoprotein inhibitor INon-inhibitor0.7301
P-glycoprotein inhibitor IIInhibitor0.8354
Renal organic cation transporterInhibitor0.7688
CYP450 2C9 substrateNon-substrate0.7907
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateSubstrate0.7353
CYP450 1A2 substrateInhibitor0.8758
CYP450 2C9 inhibitorInhibitor0.8076
CYP450 2D6 inhibitorNon-inhibitor0.8137
CYP450 2C19 inhibitorInhibitor0.6519
CYP450 3A4 inhibitorNon-inhibitor0.6308
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8913
Ames testNon AMES toxic0.8957
CarcinogenicityNon-carcinogens0.6779
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3717 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.973
hERG inhibition (predictor II)Non-inhibitor0.8733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Apotex inc
  • Barr laboratories inc
  • Corepharma llc
  • Impax laboratories inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • Watson laboratories inc florida
  • Zydus pharmaceuticals usa inc
  • Pharmacia and upjohn
  • Par pharmaceutical inc
  • Schwarz pharma inc
  • Alphapharm party ltd
  • Dava international inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Sun pharma global inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Solution, concentrateOral1 mg/mL
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral0.50 mg
TabletOral1 mg/1
TabletOral2 mg/1
Tablet, extended releaseOral.5 mg/1
Tablet, extended releaseOral1 mg/1
Tablet, extended releaseOral2 mg/1
Tablet, extended releaseOral3 mg/1
TabletOral.25 mg
TabletOral0.25 mg
TabletOral.5 mg
Kit
Tablet, orally disintegratingOral.25 mg/1
Tablet, orally disintegratingOral.5 mg/1
Tablet, orally disintegratingOral1 mg/1
Tablet, orally disintegratingOral2 mg/1
TabletOral0.5 mg
TabletOral1 mg
TabletOral2 mg
Prices
Unit descriptionCostUnit
ALPRAZolam Intensol 1 mg/ml Concentrate 30ml Bottle67.03USD bottle
Niravam 2 mg Dispersible Tablet8.53USD dispersible tablet
Xanax xr 3 mg tablet7.25USD tablet
Xanax XR 3 mg 24 Hour tablet7.1USD tablet
Niravam 2 mg tablet6.86USD tablet
Niravam 1 mg Dispersible Tablet5.42USD dispersible tablet
Xanax xr 2 mg tablet4.84USD tablet
Xanax XR 2 mg 24 Hour tablet4.73USD tablet
Niravam 0.5 mg Dispersible Tablet4.2USD dispersible tablet
Niravam 1 mg tablet4.04USD tablet
Xanax 2 mg tablet3.82USD tablet
ALPRAZolam 3 mg 24 Hour tablet3.67USD tablet
Xanax XR 1 mg 24 Hour tablet3.64USD tablet
Xanax xr 1 mg tablet3.64USD tablet
Niravam 0.25 mg Dispersible Tablet3.45USD dispersible tablet
Niravam 0.5 mg tablet3.02USD tablet
Xanax XR 0.5 mg 24 Hour tablet3.01USD tablet
Xanax xr 0.5 mg tablet2.93USD tablet
ALPRAZolam 2 mg 24 Hour tablet2.53USD tablet
Niravam 0.25 mg tablet2.43USD tablet
ALPRAZolam 1 mg 24 Hour tablet2.33USD tablet
Xanax 1 mg tablet2.29USD tablet
Alprazolam 1 mg/ml oral conc2.23USD ml
Xanax 0.5 mg tablet1.3USD tablet
Alprazolam 2 mg tablet1.22USD tablet
Xanax 0.25 mg tablet1.09USD tablet
ALPRAZolam 0.5 mg 24 Hour tablet1.07USD tablet
Alprazolam 1 mg tablet0.78USD tablet
Alprazolam 0.5 mg tablet0.67USD tablet
Alprazolam 0.25 mg tablet0.55USD tablet
Apo-Alpraz 0.5 mg Tablet0.1USD tablet
Mylan-Alprazolam 0.5 mg Tablet0.1USD tablet
Novo-Alprazol 0.5 mg Tablet0.1USD tablet
Apo-Alpraz 0.25 mg Tablet0.08USD tablet
Mylan-Alprazolam 0.25 mg Tablet0.08USD tablet
Novo-Alprazol 0.25 mg Tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6024981 No1998-04-092018-04-09Us
US6221392 No1998-04-092018-04-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point228-229.5 °CHester, J.B., Jr.; US. Patent3,681,343; August 1,1972; assigned to The Upjohn Company. Hester, J.B., Jr.; US.Patent3,781,289; December 25,1973;assigned to The Upjohn Company. Hester, J.B., Jr.; U S . Patent 3,709898; January 9,1973; assigned t o The Upjohn Company.
water solubility40 mg/L at pH 7; 12 mg/mL at pH 1.2Not Available
logP2.12BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0324 mg/mLALOGPS
logP2.23ALOGPS
logP2.37ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)18.3ChemAxon
pKa (Strongest Basic)5.08ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.07 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity98.88 m3·mol-1ChemAxon
Polarizability32.22 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0kdi-4792000000-9f1cdda14e36000955d3View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Phenyltriazole
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Azole
  • Ketimine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  2. Verster JC, Volkerts ER: Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. CNS Drug Rev. 2004 Spring;10(1):45-76. [PubMed:14978513 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 02:44